April 6, 2024 — Minneapolis Heart Institute Foundation (MHIF) highlights trends in ST-elevation myocardial infarction (STEMI), the most severe form of heart attack, at the American College of Cardiology ACC Annual Scientific Sessions We present major research that focuses on ACC.24 will be held from April 6th to 8th in Atlanta, Georgia.

The study, which analyzed nearly 8,000 STEMI patients over 20 years, found that the majority of STEMIs occur in people without a history of cardiovascular disease, and that this prevalence has not changed over time. There was found. Additionally, this study found that the risk factor profile of patients presenting with STEMI changed little over time, and the use of prophylactic medications remained low. This data is presented as part of moderated poster 1254-220, “Trends in cardiovascular risk factors and use of prophylactic cardiovascular medications in patients presenting with her ST-elevation myocardial infarction.”

The main findings of the research study reported by MHIF are:

– 70% of STEMIs still occur in people without known CVD

– Hyperlipidemia (~60% of STEMI patients) and hypertension (~60% of STEMI patients) remain major CVD risk factors in STEMI

– Average age for STEMI remains relatively young (early 60s)

– Use of preventive medications remains rare, with the majority of people not taking cholesterol medications, blood pressure medications, or aspirin before a STEMI.

“We know that the incidence of STEMI has been decreasing for decades in the United States, but it’s a little strange to see people with STEMI so similar to what we saw 20 years ago. It was a surprise.” said Michael Miedema, MD, MPH, director of the Nolan Family Cardiovascular Health Center at MHIF and lead author of the study. He added: “Although most people think of obesity and poor physical condition as the main causes of heart attacks, the main risk factors are high cholesterol and blood pressure, which are often heavily influenced by genetics.” We have made that clear.” ”

“We found that the majority of STEMIs continue to occur in the absence of preventive drugs, not despite taking preventive drugs. Patients are hesitant to start treatment for cholesterol or blood pressure. There are a lot of them, and they can be the difference between having a major heart attack and not having one.” Lead author Felipe Martinoni holds a cardiovascular prevention fellowship at the Nolan Family Center for Cardiovascular Health. He said he is currently completing his studies.

STEMI is a serious and potentially preventable manifestation of cardiovascular disease (CVD). Additionally, common treatments such as cholesterol drugs, blood pressure drugs, and antiplatelet drugs have been shown to reduce the risk of cardiovascular events such as STEMI. This study evaluated the prevalence of HE CVD risk factors and use of preventive CVD medications over the past 20 years in a large HE STEMI system in the Midwest. The study included data on 7,854 first-time STEMI patients from 2003 to 2022.

The Nolan Family Center for Cardiovascular Health, under the direction of Dr. Miedema, is dedicated to cardiovascular prevention research, according to a statement from MHIF regarding the study. Additionally, MHIF has a long history of groundbreaking research and education across a wide range of prevention-related topics, including cardiovascular risk prediction, the impact of blood pressure and cholesterol guidelines, the optimal use of preventive therapies, and the impact of nutrition and nutrition. He added that there is. Other healthy lifestyle behaviors related to cardiovascular health.

More information: www.mhif.org